Vitestro raises €12m in Series A financing
With assets of €12m through a Series A financing, Dutch Vitestro NV aims to bring the world’s first autonomous blood drawing device to the market.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
Biontech leaves; what does Germany do?
In soccer, such a transfer would raise tempers: A superstar leaves his team because he no longer trusts it to succeed. A warning sign, a headline event, fodder for weeks of debate in the media. Something similar has just happened to the biotech industry, but things remain strangely quiet in the fan block of Germanys top research – whispers at best, just whispers, but no outcry anywhere.
European VCs join US$105m financing of US Mediar Thx
Mediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures but also from more European VCs like by Gimv together with Pureos.
Iktos SA raises €15.5m in Series A financing
Paris-based AI-inspired drug discovery specialist Iktos SA has closed a €15.5m financing to expand its platform and kick-start the new CRO Iktos Robotics.
Oculis lists at Nasdaq through SPAC merger
The eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp.
Confo Therapeutics and Lilly partner to advance CFTX-1554
Drug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.
Inhalation: the potential for faster onset and fewer side-effects
There is increasing interest in delivering a range of drugs via inhalation because of the benefits it can offer patients. Lonzas Kim Shepard looks at the advantages of pulmonary delivery, and the prospect for inhaled biologics.
German HTGF IV fund closes at €493m
The fourth fund of High-Tech Gründerfonds has reached a final fund volume of €493.8m
5 Alarm Bio Ltd raises £500K in seed round
British anti-aging therapeutics developer 5 Alarm Bio Ltd has raised £500K in a seed financing for testing its lead compound FAB001 for healing chronic wounds.
High blood pressure reprograms immune system
Interferon-gamma overexpression leads to hypertension-induced damage to the blood-brain barrier by reprogrammed macrophages.